Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280259 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Emuella Flood und 9 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca plc, Patient-Centered Science, Gaithersburg, Maryland, United States of America. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Designing clinical trials with the emphasis on the patient-centered approach and focusing on clinical outcomes that are meaningful to patients is viewed as a priority by drug developers, regulatory agencies, payers, clinicians, and patients. This study aimed to capture information on clinical trial endpoints that would be most important and relevant for patients with advanced breast cancer, based on patient-reported outcomes.
Methods
Patients with either advanced triple-negative breast cancer [TNBC] and a maximum of two lines of systemic therapy or hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR+/HER2−] breast cancer and a maximum of three lines of systemic therapy, participated in semi-structured concept elicitation interviews. Concept saturation was assessed. A sign, symptom, or impact was defined as “salient” if mentioned by ≥ 60% of participants, with an average bother rating of ≥ 5 (0–10 Scale). Participants were also asked about treatment priorities and to evaluate hypothetical scenarios showing different health-related functioning and quality-of-life treatment outcomes, using graphical representations.
Results
Thirty-two participants (97% women; aged 29+ years) with TNBC (n = 17) or HR+/HER2− breast cancer (n = 15) provided generally similar reports on symptom experience, with fatigue and pain being most salient, though importance of certain treatment-related symptoms varied between the two groups. Patients reported consistent perspectives on the importance of treatment outcomes: when considering a new treatment, they prioritized efficacy of the therapy, acceptable tolerability, stability, predictability of symptoms over time, and the duration of preserved health-related quality of life and physical functioning. The meaningful difference in preserved physical functioning was 2–3 months for 46% of participants with TNBC, whereas for most participants with HR+/HER2− breast cancer it started from 6–7 months. Both groups of participants found it easier to accept some toxicity at the beginning of therapy if it was followed by improvement, as opposed to improvement followed by deterioration.
Conclusion
The results may help to inform the design of patient-centered clinical trials, to interpret health-related quality of life and/or patient-reported outcomes, and to optimize care for patients with advanced breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AstraZeneca plc, Patient-Centered Science, Gaithersburg, Maryland, United States of America.
- IQVIA Real World Solutions, Patient-Centered Solutions, London, United Kingdom.
- AstraZeneca plc, R&D Oncology, Cambridge, United Kingdom.
- IQVIA Real World Solutions, Patient-Centered Solutions, New York, New York, United States of America.
- IQVIA Real World Solutions, Patient-Centered Solutions, Courbevoie, France.
ORCID-Profile: Emuella Flood
Zitieren
APA
Flood, E., Krasnow, A., Orbegoso, C., Karantzoulis, S., Bailey, J., Bayet, S., Elghouayel, A., Foxley, A., Sommavilla, R., & Schiavon, G. (2023). Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0280259
Vancouver
Flood E, Krasnow A, Orbegoso C, Karantzoulis S, Bailey J, Bayet S, et al. Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer. PLOS ONE. 2023. doi:10.1371/journal.pone.0280259
BibTeX
@article{Flood2023,
author = {Flood, Emuella and Krasnow, Anna and Orbegoso, Cecilia and Karantzoulis, Stella and Bailey, Julie and Bayet, Solène and Elghouayel, Arthur and Foxley, Andrew and Sommavilla, Roberto and Schiavon, Gaia},
title = {Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280259}
}
EUVIMED